title: OUTCOMES OF TREATMENT OF CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CENTRAL SEROUS CHORIORETINOPATHY WITH INTRAVITREAL ANTIANGIOGENIC AGENTS.
abstract: OBJECTIVE
  To report clinical characteristics and treatment outcomes from the largest case series of choroidal neovascularization secondary to central serous chorioretinopathy.
  
  
  METHODS
  Retrospective analysis of 46 eyes of 43 consecutive subjects. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were the proportion of eyes that had improved (3 or more lines), stable (within ±1 line), or decreased (3 or more lines) vision at the final visit as compared with baseline examination. Secondary efficacy outcomes included change in visual acuity at final follow-up, number of injections, treatment-free interval, and adverse events.
  
  
  RESULTS
  Mean age was 57.56 years (range 29-79 years). Mean follow-up duration was 38.3 months ± 58.9 months. More than 3 lines of improvement in 12 eyes (26%), vision was stable (within ±1 line) in 19 eyes (41.3%), and >3 lines of loss was noted in 6 eyes (13%). Mean change in the number of lines was 1.16 ± 3.74. Mean number of anti-vascular endothelial growth factor injections during the follow-up was 4.45 ± 4.1. The longest treatment-free interval was 8.9 months ± 7.5 months. There were no adverse events noted.
  
  
  CONCLUSIONS
  Anti-vascular endothelial growth factor therapy as a primary therapy for choroidal neovascularization secondary to central serous chorioretinopathy is safe and efficacious, without any serious adverse events.
authors.affiliation: *Smt. Kanuri Santhamma Retina Vitreous Centre, L. V. Prasad Eye Institute, Hyderabad, India; †Vitreoretinal Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; ‡San Giuseppe Hospital, University Eye Clinic, Milan, Italy; §Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico; ¶Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio; **Instituto de Cirugia Ocular, San José, Costa Rica; ††Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; ‡‡Department of Ophthalmology, Universidade Estadual de Londrina, Londrina, Brazil; §§Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; and ¶¶Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon.
authors.forename: Jay
authors.initials: J
authors.lastname: Chhablani
authors.forename: Igor
authors.initials: I
authors.lastname: Kozak
authors.forename: Francesco
authors.initials: F
authors.lastname: Pichi
authors.forename: Megan
authors.initials: M
authors.lastname: Chenworth
authors.forename: Maria H
authors.initials: MH
authors.lastname: Berrocal
authors.forename: Rumneek
authors.initials: R
authors.lastname: Bedi
authors.forename: Rishi P
authors.initials: RP
authors.lastname: Singh
authors.forename: Lihteh
authors.initials: L
authors.lastname: Wu
authors.forename: Catherine
authors.initials: C
authors.lastname: Meyerle
authors.forename: Antonio Marcelo
authors.initials: AM
authors.lastname: Casella
authors.forename: Ahmad
authors.initials: A
authors.lastname: Mansour
authors.forename: Ziad
authors.initials: Z
authors.lastname: Bashshur
authors.forename: Antonella
authors.initials: A
authors.lastname: Scorza
authors.forename: Paola
authors.initials: P
authors.lastname: Carrai
authors.forename: Paolo
authors.initials: P
authors.lastname: Nucci
authors.forename: J Fernando
authors.initials: JF
authors.lastname: Arevalo
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D056833:Central Serous Chorioretinopathy / Q000150:complications* / Q000188:drug therapy; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000008:administration & dosage*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab